Zydus Gains USFDA Nod for Innovative Methylene Blue Injection
By Aayush KhannaZydus Lifesciences (NS:ZYDU) Limited, along with its subsidiaries/affiliates, has secured the final nod from the United States Food and Drug Administration (USFDA) for...
Neutral
or
Zydus Lifesciences News & Analysis
-
-
CLSA downgrades Zydus Lifesciences to 'outperform' with a price target of ₹660.00
An analyst from CLSA downgraded Zydus Lifesciences (NS: ZYDU) from 'buy' to 'outperform' with a price target of ₹660.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Prabhudas Lilladher maintains Zydus Lifesciences at 'accumulate' with a price target of ₹670.00
An analyst from Prabhudas Lilladher maintained Zydus Lifesciences (NS: ZYDU) at 'accumulate' with a price target of ₹670.00 from a prior price target of %currency%%price%. Prior to this...
-
Antique Research maintains Zydus Lifesciences at 'hold' with a price target of ₹615.00
An analyst from Antique Research maintained Zydus Lifesciences (NS: ZYDU) at 'hold' with a price target of ₹615.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
JPMorgan maintains Zydus Lifesciences at 'neutral' with a price target of ₹570.00
An analyst from JPMorgan maintained Zydus Lifesciences (NS: ZYDU) at 'neutral' with a price target of ₹570.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus...
-
Zydus Lifesciences acquires UK LiqMeds Group for 68 mn pounds
Chennai, Oct 31 (IANS) Indian pharmaceutical major Zydus Lifesciences (NS:ZYDU) Ltd on Tuesday said it has signed an agreement to acquire the UK-headquartered LiqMeds Group of companies for...
-
JPMorgan initiates coverage of Zydus Lifesciences at 'neutral' with a price target of ₹575.00
An analyst from JPMorgan initiated coverage of Zydus Lifesciences (NS: ZYDU) at 'neutral' with a price target of ₹575.00. Prior to this rating, Zydus Lifesciences had 17 buy ratings, 11...
-
Macquarie maintains Zydus Lifesciences at 'underperform' with a price target of INR490.00
An analyst from Macquarie maintained Zydus Lifesciences (NS: ZYDU) at 'underperform' with a price target of INR490.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Jefferies maintains Zydus Lifesciences at 'hold' with a price target of INR630.00
An analyst from Jefferies maintained Zydus Lifesciences (NS: ZYDU) at 'hold' with a price target of INR630.00. Prior to this rating, Zydus Lifesciences had 17 buy ratings, 9 hold ratings,...
-
HSBC maintains Zydus Lifesciences at 'hold' with a price target of INR615.00
An analyst from HSBC maintained Zydus Lifesciences (NS: ZYDU) at 'hold' with a price target of INR615.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus...
-
Nomura/Instinet maintains Zydus Lifesciences at 'buy' with a price target of INR747.00
An analyst from Nomura/Instinet maintained Zydus Lifesciences (NS: ZYDU) at 'buy' with a price target of INR747.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Investec upgrades Zydus Lifesciences to 'hold' with a price target of INR685.00
An analyst from Investec upgraded Zydus Lifesciences (NS: ZYDU) from 'sell' to 'hold' with a price target of INR685.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
BofA Securities maintains Zydus Lifesciences at 'neutral' with a price target of INR660.00
An analyst from BofA Securities maintained Zydus Lifesciences (NS: ZYDU) at 'neutral' with a price target of INR660.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
ONGC, Apollo Hospitals, HAL, Nykaa Among 227 Cos to Release Q1 Today
By Malvika Gurung Investing.com -- A total of a whopping 227 listed companies are scheduled to release their financial earnings for the quarter ended June 30, 2023, on Friday, August 11,...
-
Citi maintains Zydus Lifesciences at 'sell' with a price target of INR490.00
An analyst from Citi maintained Zydus Lifesciences (NS: ZYDU) at 'sell' with a price target of INR490.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus...
-
HSBC maintains Zydus Lifesciences at 'hold' with a price target of INR580.00
An analyst from HSBC maintained Zydus Lifesciences (NS: ZYDU) at 'hold' with a price target of INR580.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus...
-
Elara Securities India maintains Zydus Lifesciences at 'buy' with a price target of INR685.00
An analyst from Elara Securities India maintained Zydus Lifesciences (NS: ZYDU) at 'buy' with a price target of INR685.00 from a prior price target of %currency%%price%. Prior to this...
-
Zydus Life Receives USFDA Approval for Drug Treating Smoking Addiction
By Malvika Gurung Investing.com -- The pharmaceutical company Zydus Lifesciences (NS:ZYDU) has received approval for a drug called Varenicline Tablets from the United States Food and Drug...
-
HSBC maintains Zydus Lifesciences at 'hold' with a price target of INR510.00
An analyst from HSBC maintained Zydus Lifesciences (NS: ZYDU) at 'hold' with a price target of INR510.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus...
-
Jefferies maintains Zydus Lifesciences at 'buy' with a price target of INR585.00
An analyst from Jefferies maintained Zydus Lifesciences (NS: ZYDU) at 'buy' with a price target of INR585.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus...
-
SBI, ITC, GAIL, IndiGo to Release Q4 Earning on May 18
By Malvika Gurung Investing.com -- Indian equity benchmark indices gained on Thursday amid an improvement in global cues, with headlines Nifty50 rising 0.3% at 18,232.67 levels and Sensex...
-
Major Companies Set to Release Q4 Earnings This Week
By Malvika Gurung Investing.com -- The week starting on May 14, 2023, will be lined with more than 500 companies set to release earnings results for the quarter ended March 31, 2023. This...
-
Jefferies maintains Zydus Lifesciences at Buy, PT $575.00
A Jefferies analyst maintained Zydus Lifesciences (NS: ZYDU) at Buy and a price target of $575.00 from a prior price target of %currency%%price%. Prior to this rating, Zydus Lifesciences...
-
Morgan Stanley maintains Zydus Lifesciences at Overweight
A Morgan Stanley analyst maintained Zydus Lifesciences (NS: ZYDU) at Overweight and a price target of $513.00. Prior to this rating, Zydus Lifesciences had 19 buy ratings, 7 hold ratings,...
-
Investec maintains Zydus Lifesciences at Sell
An Investec analyst maintained Zydus Lifesciences (NS: ZYDU) at Sell and a price target of $430.00. Prior to this rating, Zydus Lifesciences had 17 buy ratings, 10 hold ratings, and 5...
-
Stock jumps 9% after it reports better than expected net profit in Q3
Volumes spurt at Zydus Lifesciences’ counter after the company reported better-than-estimated earnings for the October to December quarter. Its shares gained 9.63 percent to reach an...
-
Nepal bans import of medicines from 16 Indian companies
Kathmandu, Dec 20 (IANS) Nepal's Department of Drug Administration has published a list of 16 Indian pharmaceutical companies, including Divya Pharmacy that manufactures Yoga guru Ramdev's...
-
Mkt-Mover Alert: Key Q2 Results Ahead- Tata Motors, LIC, Coal India, BPCL & More
By Malvika Gurung Investing.com -- The domestic market made a higher closing on Friday, snapping two sessions of losses, with the equity benchmark indices ending the week with up to 2%...
-
NSE Indices Rejig on Sept 30: Hefty Inflows Likely in Nifty50, Nifty Bank & More
By Malvika Gurung Investing.com -- The flagship company of Adani (NS:APSE) Group, Adani Enterprises (NS:ADEL) will make its way into one of the most-tracked benchmark equity indices...
-
Nifty50 Rejig: Adani Enterprises to Replace Shree Cement; Nifty Next 50 Rejig
By Malvika Gurung Investing.com -- The flagship company of the world’s third richest man Gautam Adani, Adani Enterprises (NS:ADEL) will make its way into one of the most-tracked benchmark...
-
Stocks Under Focus: HDFC Twins, Coal India, NTPC, Eicher, IRCTC & More
By Malvika Gurung Investing.com -- HDFC (NS:HDFC): The mortgage lender has raised its benchmark lending rate by 25 basis points, coming into effect from Aug 9, 2022. This is the sixth rate...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
